Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several administration and missed-dose logistics claims match the label, but many other claims (food/PK, nausea timing, pen hold time, GI meal strategies, double-dosing) are not supported by the provided label text, and the response does not address key on-label safety sections (contraindications/boxed warnings/major precautions), limiting label adherence.
Category Scores
Accurate Statements
Ozempic (semaglutide) is a once-weekly subcutaneous injection.
Supported by label section 2.1 (Administer OZEMPIC once weekly; inject subcutaneously).
Ozempic should be taken on the same day each week.
Supported by label section 2.1 (Administer once weekly, on the same day each week).
Ozempic can be administered with or without food.
Supported by label section 2.1 (with or without meals).
Ozempic can be administered at any time of day (morning, noon, or evening) as long as it is consistent weekly.
Supported by label section 2.1 (at any time of the day).
No specific meal timing is required for Ozempic.
Supported by label section 2.1 (with or without meals).
Ozempic can be injected subcutaneously into the abdomen, thigh, or upper arm.
Supported by label section 2.1 (inject subcutaneously in the abdomen, thigh, or upper arm).
Injection sites should be rotated weekly.
Supported by label section 2.1 (use a different injection site each week when injecting in the same body region).
If a dose of Ozempic is missed, it should be taken within 5 days of the missed dose.
Supported by label section 2.1 (administer as soon as possible within 5 days after the missed dose).
If a missed Ozempic dose is more than 5 days late, it should be skipped and the next scheduled dose should be resumed.
Supported by label section 2.1 (if more than 5 days have passed, skip and administer next dose on regularly scheduled day).
Unsupported Statements
Food has minimal effect on Ozempic pharmacokinetics.
Not supported in the provided label sections (2.1/2.2 text does not state PK effects of food).
Meal timing does not affect Ozempic absorption.
Not supported in the provided label sections.
After subcutaneous injection, the pen should be held for 5–10 seconds.
Not supported in the provided label sections.
There is no need to eat immediately before or after Ozempic administration.
The label supports with/without meals but the specific 'immediately before or after' statement is not explicitly supported in the provided label text.
Nausea is a common side effect of Ozempic.
No adverse reaction frequency/support is provided in the included label text for nausea.
Nausea often occurs most after meals.
Not supported in the provided label sections.
Patients may inject 1–2 days before heavy meals to ease GI symptoms, but this is not medically required.
Not supported in the provided label sections.
Patients may eat smaller, bland meals after injection if needed.
Not supported in the provided label sections.
Double-dosing Ozempic after a missed dose should not be done.
The provided label text addresses missed-dose timing/skip rules but does not explicitly state a 'no double-dosing' instruction.
Meal timing remains irrelevant when handling missed Ozempic doses.
The label text provided covers missed-dose timing, not meal-timing considerations for missed doses.
Contradictions
Important Omissions
Key FDA label safety content such as Boxed Warnings/Contraindications/Warnngs and Precautions (beyond GI severe reactions excerpt), and major counseling points is not addressed in the AI claims list.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
While several dosing and administration logistics are on-label, multiple unsupported claims relate to GI symptom management, food/PK/absorption implications, injection procedure timing, and missed-dose handling. Additionally, the response does not cover critical label safety elements (e.g., contraindications and major warnings/precautions), which are material for safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Many non-mechanistic label-specific claims (food/PK, nausea timing/frequency, pen hold time, meal strategies, double-dosing prohibition) are not supported by the provided label text, and critical safety label sections are omitted.
Suggested Improvement
Restrict administration guidance strictly to label-supported instructions (2.1/2.2) and remove or qualify statements not present in the supplied label text. Add coverage of contraindications and boxed warnings/warnings/precautions from the label when performing comprehensive label alignment.